hotspot -WSS

hotspot

author：knowledge 2025-09-27 12:48:42 - browse：5573

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： The untold story of TV’s first prescription drug ad

explore

WSS

Cigna, Humana reportedly in talks to merge

Medicare drug price negotiation hearing pits pharma v Biden admin

State of the Union pitch: Bigger Medicare drug price negotiations

Why Talkspace is targeting Medicare, a tricky market

Fetal cell organoids grown from amniotic fluid, study finds

Cigna, Humana reportedly in talks to merge

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Biden's 'march

Trump demands the U.S. pay no more for drugs than other countries … again

The untold story of TV’s first prescription drug ad

State Dept. review finds Biden bears some blame for Afghanistan failures

The untold story of TV’s first prescription drug ad

DIEP, the 'gold standard' of breast reconstruction, is under threat

For AI in health care standards, federal regulators join with industry group

Drug repurposing or repositioning? The language matters

Disappointing trial forces Pfizer to pivot on obesity medicine plans

focus

Microsoft's Peter Lee: Generative AI could help doctors be more human

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

$1 billion proposal to grow Boston, Massachusetts biotech

CDC director unscathed in first congressional testimony

UnitedHealth’s Optum accused of antitrust violations in California

As biotech industry slumps, bioscience job market is upside down

leisure time

explore

explore

entertainment